These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 946595)

  • 41. [Antitumor activity of a novel analog of cytarabine, 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 5'-(sodium octadecyl phosphate) monohydrate (YNK01)].
    Nagahata T; Shibasaki C; Ishii T; Uchida T; Arakawa M; Kusama K; Ekimoto H; Takahashi K
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1437-45. PubMed ID: 2389942
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of the mechanism of activation of 9-beta-D-arabinofuranosyladenine in human lymphoid cells using mutants deficient in nucleoside kinases.
    Verhoef V; Sarup J; Fridland A
    Cancer Res; 1981 Nov; 41(11 Pt 1):4478-83. PubMed ID: 6272978
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The enhanced cytotoxicity of combinations of 1-beta-D-arabinofuranosylcytosine and methotrexate.
    Edelstein M; Vietti T; Valeriote F
    Cancer Res; 1975 Jun; 35(6):1555-8. PubMed ID: 1131822
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interaction of 9-beta-D-arabinofuranosyladenine, 9-beta-D-arabinofuranosyladenine 5'-monophosphate, and 9-beta-D-arabinofuranosyladenine 5'-triphosphate with S-adenosylhomocysteinase.
    Helland S; Ueland PM
    Cancer Res; 1981 Feb; 41(2):673-8. PubMed ID: 6160909
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
    Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J
    Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correlation of mouse tissue distribution of arabinosylcytosine in vivo with enzymatic activities in vitro.
    Ho DH
    Drug Metab Dispos; 1976; 4(3):296-300. PubMed ID: 6236
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Initial rate kinetics and evidence for duality of mediated transport of adenosine, related purine nucleosides, and nucleoside analogues in L1210 cells.
    Chello PL; Sirotnak FM; Dorick DM; Yang CH; Montgomery JA
    Cancer Res; 1983 Jan; 43(1):97-103. PubMed ID: 6847787
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacology of 5'-esters of 1-beta-D-arabinofuranosylcytosine.
    Ho DH; Neil GL
    Cancer Res; 1977 Jun; 37(6):1640-3. PubMed ID: 870178
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of cholesterol content on antitumor activity and toxicity of liposome-encapsulated 1-beta-D-arabinofuranosylcytosine in vivo.
    Ganapathi R; Krishan A; Wodinsky I; Zubrod CG; Lesko LJ
    Cancer Res; 1980 Mar; 40(3):630-3. PubMed ID: 7471083
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Determinants of Ara-C action: biochemical consideration.
    Rustum YM; Slocum HK; Li ZR
    Prog Clin Biol Res; 1983; 132E():107-20. PubMed ID: 6689076
    [No Abstract]   [Full Text] [Related]  

  • 51. S-adenosylhomocysteine and S-adenosylhomocysteine hydrolase in various tissues of mice given injections of 9-beta-D-arabinofuranosyladenine.
    Helland S; Ueland PM
    Cancer Res; 1983 Apr; 43(4):1847-50. PubMed ID: 6831422
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination effects of Ara-C and 5-fluorodeoxyuridine against leukemia cells in vitro and in mice.
    Rauko P; Bauer W; Horvath Z; Höchtl T; Saiko P; Karl D; Schott H; Fritzer-Szekeres M; Novotny L; Szekeres T
    Anticancer Res; 2003; 23(5A):3841-6. PubMed ID: 14666686
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Correlation of cytotoxicity with total intracellular exposure to 9-beta-D-arabinofuranosyladenine 5'-triphosphate.
    Shewach DS; Plunkett W
    Cancer Res; 1982 Sep; 42(9):3637-41. PubMed ID: 6179604
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Studies of the relationship between adenosine deaminase and immune function.
    Burridge PW; Paetkau V; Henderson JF
    J Immunol; 1977 Aug; 119(2):675-8. PubMed ID: 301901
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical pharmacology of 9-beta-D-arabinofuranosyladenine in combination with 2'-deoxycoformycin.
    Agarwal RP; Blatt J; Miser J; Sallan S; Lipton JM; Reaman GH; Holcenberg J; Poplack DG
    Cancer Res; 1982 Sep; 42(9):3884-6. PubMed ID: 6980706
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.
    Kreis W; Hession C; Soricelli A; Scully K
    Cancer Treat Rep; 1977 Oct; 61(7):1355-64. PubMed ID: 589601
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 2'-deoxycoformycin (DCF) and 9-beta-D-arabinofuranosyladenine (Ara-A) in the treatment of refractory acute myelocytic leukemia.
    Gray DP; Grever MR; Siaw MF; Coleman MS; Balcerzak SP
    Cancer Treat Rep; 1982 Feb; 66(2):253-7. PubMed ID: 6976833
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Selection of 9-beta-D-arabinofuranosyladenine-resistant human T-lymphoblasts with altered ribonucleotide reductase activity.
    Fridland A
    Cancer Res; 1984 Oct; 44(10):4328-32. PubMed ID: 6380707
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of 1-beta-D-arabinofuranosylcytosine incorporation on eukaryotic DNA template function.
    Kufe DW; Munroe D; Herrick D; Egan E; Spriggs D
    Mol Pharmacol; 1984 Jul; 26(1):128-34. PubMed ID: 6431261
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Problems of antineoplastic effects by PLDR (potential lethal damage repair) inhibitor--pharmacokinetics].
    Sougawa M; Akagi K; Yoshii G; Tanaka Y
    Gan No Rinsho; 1984 Nov; 30(14):1787-92. PubMed ID: 6334757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.